Manager, Monitoring & Site Management

ABOUT ALIMENTIV Alimentiv is a global CRO with a singular focus: advancing therapies for patients with gastrointestinal diseases. GI is our WHY and for more than 30 years that purpose has driven our scientific rigour, operational excellence, and deep therapeutic expertise, including supporting more than 70% of IBD compounds in development. We operate as a private, profit-with-purpose company, channeling our commercial success back into scientific research, technology, and our people. With approximately 700 people across multiple countries and three service lines, we are growing deliberately, and the capability of our leaders and our organization is central to how we get there. If you want to do meaningful work, build something real, and invest back in research that changes lives — we want to meet you. THE OPPORTUNITY In this role, you will lead the day-to-day delivery of our Clinical Monitoring capability, with a focus on European CRAs. You will bring structure, clarity, and accountability to how we plan, manage, and continuously improve this critical function. Your scope spans both operational leadership and strategic impact. From shaping policies and strengthening processes, to ensuring the quality and integrity of our clinical work at every level, you will play a central role. You will oversee resource planning, performance management, and compliance, ensuring our teams and partners deliver consistently high standards aligned with both regulatory expectations and industry best practice. Working closely with sponsors and research partners, you will act as a trusted representative of our clinical monitoring and project teams throughout the full study lifecycle. You will bring expertise, credibility, and a solutions-oriented mindset to every interaction. Positions available: 1; this opportunity is cross-listed in multiple locations. At this time, the position is open to those residing in Germany, United Kingdom, Ireland, Poland, Hungary, and Romania.  Closing date: June 12th, 2026, or later until successful candidate identified.